#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Eutrophication of natural water sources is closely linked to the distinctive appearance of massive and episodic proliferations of cyanobacteria .
2-1	16-30	Eutrophication	abstract[2]	new[2]	_	_
2-2	31-33	of	abstract[2]	new[2]	_	_
2-3	34-41	natural	abstract[2]|substance[4]	new[2]|new[4]	_	_
2-4	42-47	water	abstract[2]|substance|substance[4]	new[2]|new|new[4]	coref	5-30[29_0]
2-5	48-55	sources	abstract[2]|substance[4]	new[2]|new[4]	_	_
2-6	56-58	is	_	_	_	_
2-7	59-66	closely	_	_	_	_
2-8	67-73	linked	_	_	_	_
2-9	74-76	to	_	_	_	_
2-10	77-80	the	abstract[5]	new[5]	_	_
2-11	81-92	distinctive	abstract[5]	new[5]	_	_
2-12	93-103	appearance	abstract[5]	new[5]	_	_
2-13	104-106	of	abstract[5]	new[5]	_	_
2-14	107-114	massive	abstract[5]|object[6]	new[5]|new[6]	_	_
2-15	115-118	and	abstract[5]|object[6]	new[5]|new[6]	_	_
2-16	119-127	episodic	abstract[5]|object[6]	new[5]|new[6]	_	_
2-17	128-142	proliferations	abstract[5]|object[6]	new[5]|new[6]	_	_
2-18	143-145	of	abstract[5]|object[6]	new[5]|new[6]	_	_
2-19	146-159	cyanobacteria	abstract[5]|object[6]|animal	new[5]|new[6]|new	coref	3-21
2-20	160-161	.	_	_	_	_

#Text=These prokaryotic organisms do not systematically carry the expressed genes for toxin production , yet about 40 of the 150 cyanobacteria genera do possess these genes .
3-1	162-167	These	animal[8]	new[8]	_	_
3-2	168-179	prokaryotic	animal[8]	new[8]	_	_
3-3	180-189	organisms	animal[8]	new[8]	_	_
3-4	190-192	do	_	_	_	_
3-5	193-196	not	_	_	_	_
3-6	197-211	systematically	_	_	_	_
3-7	212-217	carry	_	_	_	_
3-8	218-221	the	abstract[9]	new[9]	coref	3-25[15_9]
3-9	222-231	expressed	abstract[9]	new[9]	_	_
3-10	232-237	genes	abstract[9]	new[9]	_	_
3-11	238-241	for	abstract[9]	new[9]	_	_
3-12	242-247	toxin	abstract[9]|substance|abstract[11]	new[9]|new|new[11]	coref	9-23[66_11]
3-13	248-258	production	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-14	259-260	,	_	_	_	_
3-15	261-264	yet	time[12]	new[12]	_	_
3-16	265-270	about	time[12]	new[12]	_	_
3-17	271-273	40	time[12]	new[12]	_	_
3-18	274-276	of	time[12]	new[12]	_	_
3-19	277-280	the	time[12]|animal[14]	new[12]|new[14]	_	_
3-20	281-284	150	time[12]|animal[14]	new[12]|new[14]	_	_
3-21	285-298	cyanobacteria	time[12]|animal|animal[14]	new[12]|giv|new[14]	coref	7-16[48_0]
3-22	299-305	genera	time[12]|animal[14]	new[12]|new[14]	_	_
3-23	306-308	do	_	_	_	_
3-24	309-316	possess	_	_	_	_
3-25	317-322	these	abstract[15]	giv[15]	_	_
3-26	323-328	genes	abstract[15]	giv[15]	_	_
3-27	329-330	.	_	_	_	_

#Text=For more than two decades , microcystins ( MCs ) have been the main family of cyanopeptides extensively studied .
4-1	331-334	For	_	_	_	_
4-2	335-339	more	substance[17]	new[17]	_	_
4-3	340-344	than	substance[17]	new[17]	_	_
4-4	345-348	two	time[16]|substance[17]	new[16]|new[17]	_	_
4-5	349-356	decades	time[16]|substance[17]	new[16]|new[17]	_	_
4-6	357-358	,	substance[17]	new[17]	_	_
4-7	359-371	microcystins	substance[17]	new[17]	_	_
4-8	372-373	(	_	_	_	_
4-9	374-377	MCs	object	new	coref	5-33
4-10	378-379	)	_	_	_	_
4-11	380-384	have	_	_	_	_
4-12	385-389	been	_	_	_	_
4-13	390-393	the	abstract[19]	new[19]	_	_
4-14	394-398	main	abstract[19]	new[19]	_	_
4-15	399-405	family	abstract[19]	new[19]	_	_
4-16	406-408	of	abstract[19]	new[19]	_	_
4-17	409-422	cyanopeptides	abstract[19]|abstract	new[19]|new	coref	7-6
4-18	423-434	extensively	_	_	_	_
4-19	435-442	studied	_	_	_	_
4-20	443-444	.	_	_	_	_

#Text=This dominance has been triggered by tragic incidents , such as in a Brazilian hospital in 1996 , where 52 patients undergoing dialysis succumbed to liver failure caused by contaminated water with MCs .
5-1	445-449	This	abstract[21]	new[21]	_	_
5-2	450-459	dominance	abstract[21]	new[21]	_	_
5-3	460-463	has	_	_	_	_
5-4	464-468	been	_	_	_	_
5-5	469-478	triggered	_	_	_	_
5-6	479-481	by	_	_	_	_
5-7	482-488	tragic	event[22]	new[22]	_	_
5-8	489-498	incidents	event[22]	new[22]	_	_
5-9	499-500	,	event[22]	new[22]	_	_
5-10	501-505	such	event[22]	new[22]	_	_
5-11	506-508	as	event[22]	new[22]	_	_
5-12	509-511	in	event[22]	new[22]	_	_
5-13	512-513	a	event[22]|place[23]	new[22]|new[23]	_	_
5-14	514-523	Brazilian	event[22]|place[23]	new[22]|new[23]	_	_
5-15	524-532	hospital	event[22]|place[23]	new[22]|new[23]	_	_
5-16	533-535	in	event[22]|place[23]	new[22]|new[23]	_	_
5-17	536-540	1996	event[22]|place[23]|time	new[22]|new[23]|new	_	_
5-18	541-542	,	_	_	_	_
5-19	543-548	where	_	_	_	_
5-20	549-551	52	person[25]	new[25]	_	_
5-21	552-560	patients	person[25]	new[25]	_	_
5-22	561-571	undergoing	_	_	_	_
5-23	572-580	dialysis	event	new	ana	6-2
5-24	581-590	succumbed	_	_	_	_
5-25	591-593	to	_	_	_	_
5-26	594-599	liver	object|abstract[28]	new|new[28]	coref	11-8[74_0]
5-27	600-607	failure	abstract[28]	new[28]	_	_
5-28	608-614	caused	_	_	_	_
5-29	615-617	by	_	_	_	_
5-30	618-630	contaminated	substance[29]	giv[29]	coref	6-19[0_29]
5-31	631-636	water	substance[29]	giv[29]	_	_
5-32	637-641	with	substance[29]	giv[29]	_	_
5-33	642-645	MCs	substance[29]|substance	giv[29]|giv	coref	7-13
5-34	646-647	.	_	_	_	_

#Text=Following this , the World Health Organization ( WHO ) has suggested regulation levels for MC-LR in drinking water ( 1 µg L−1 ) which was extended by the US EPA to MC-LR equivalents to include more congeners and other cyanotoxins .
6-1	648-657	Following	_	_	_	_
6-2	658-662	this	event	giv	_	_
6-3	663-664	,	_	_	_	_
6-4	665-668	the	organization[32]	new[32]	_	_
6-5	669-674	World	organization[32]	new[32]	_	_
6-6	675-681	Health	organization[32]	new[32]	_	_
6-7	682-694	Organization	organization[32]	new[32]	_	_
6-8	695-696	(	_	_	_	_
6-9	697-700	WHO	_	_	_	_
6-10	701-702	)	_	_	_	_
6-11	703-706	has	_	_	_	_
6-12	707-716	suggested	_	_	_	_
6-13	717-727	regulation	abstract|abstract[34]	new|new[34]	_	_
6-14	728-734	levels	abstract[34]	new[34]	_	_
6-15	735-738	for	abstract[34]	new[34]	_	_
6-16	739-744	MC-LR	abstract[34]|substance	new[34]|new	coref	6-33
6-17	745-747	in	_	_	_	_
6-18	748-756	drinking	_	_	_	_
6-19	757-762	water	substance	giv	_	_
6-20	763-764	(	_	_	_	_
6-21	765-766	1	quantity[38]	new[38]	_	_
6-22	767-769	µg	abstract|quantity[38]	new|new[38]	_	_
6-23	770-773	L−1	quantity[38]	new[38]	_	_
6-24	774-775	)	_	_	_	_
6-25	776-781	which	_	_	_	_
6-26	782-785	was	_	_	_	_
6-27	786-794	extended	_	_	_	_
6-28	795-797	by	_	_	_	_
6-29	798-801	the	organization[40]	new[40]	_	_
6-30	802-804	US	place|organization[40]	new|new[40]	_	_
6-31	805-808	EPA	organization[40]	new[40]	_	_
6-32	809-811	to	_	_	_	_
6-33	812-817	MC-LR	substance|object[42]	giv|new[42]	_	_
6-34	818-829	equivalents	object[42]	new[42]	_	_
6-35	830-832	to	_	_	_	_
6-36	833-840	include	_	_	_	_
6-37	841-845	more	substance[43]	new[43]	coref	9-7[60_43]
6-38	846-855	congeners	substance[43]	new[43]	_	_
6-39	856-859	and	_	_	_	_
6-40	860-865	other	object[44]	new[44]	coref	15-15[98_44]
6-41	866-877	cyanotoxins	object[44]	new[44]	_	_
6-42	878-879	.	_	_	_	_

#Text=However , several families of cyanopeptides have long been identified along with MCs isolated from common cyanobacteria , i. e. , Microcystis sp .
7-1	880-887	However	_	_	_	_
7-2	888-889	,	_	_	_	_
7-3	890-897	several	abstract[45]	new[45]	ana	8-2[0_45]
7-4	898-906	families	abstract[45]	new[45]	_	_
7-5	907-909	of	abstract[45]	new[45]	_	_
7-6	910-923	cyanopeptides	abstract[45]|object	new[45]|giv	coref	10-2
7-7	924-928	have	_	_	_	_
7-8	929-933	long	_	_	_	_
7-9	934-938	been	_	_	_	_
7-10	939-949	identified	_	_	_	_
7-11	950-955	along	_	_	_	_
7-12	956-960	with	_	_	_	_
7-13	961-964	MCs	object	giv	coref	11-1
7-14	965-973	isolated	_	_	_	_
7-15	974-978	from	_	_	_	_
7-16	979-985	common	animal[48]	giv[48]	coref	15-7[0_48]
7-17	986-999	cyanobacteria	animal[48]	giv[48]	_	_
7-18	1000-1001	,	_	_	_	_
7-19	1002-1004	i.	_	_	_	_
7-20	1005-1007	e.	_	_	_	_
7-21	1008-1009	,	_	_	_	_
7-22	1010-1021	Microcystis	abstract|animal[50]	new|new[50]	_	_
7-23	1022-1024	sp	animal[50]	new[50]	_	_
7-24	1025-1026	.	_	_	_	_

#Text=Amongst them , cyanopeptolins , anabaenopeptins ( APs ) , aerucyclamides , aeruginosines , and microginins are to mention when specifying the dominant families .
8-1	1027-1034	Amongst	_	_	_	_
8-2	1035-1039	them	abstract	giv	coref	8-22[58_0]
8-3	1040-1041	,	_	_	_	_
8-4	1042-1056	cyanopeptolins	person	new	_	_
8-5	1057-1058	,	_	_	_	_
8-6	1059-1074	anabaenopeptins	abstract	new	appos	8-8
8-7	1075-1076	(	_	_	_	_
8-8	1077-1080	APs	abstract	giv	coref	14-9
8-9	1081-1082	)	_	_	_	_
8-10	1083-1084	,	_	_	_	_
8-11	1085-1099	aerucyclamides	abstract	new	_	_
8-12	1100-1101	,	_	_	_	_
8-13	1102-1115	aeruginosines	abstract	new	_	_
8-14	1116-1117	,	_	_	_	_
8-15	1118-1121	and	_	_	_	_
8-16	1122-1133	microginins	substance	new	_	_
8-17	1134-1137	are	_	_	_	_
8-18	1138-1140	to	_	_	_	_
8-19	1141-1148	mention	_	_	_	_
8-20	1149-1153	when	_	_	_	_
8-21	1154-1164	specifying	_	_	_	_
8-22	1165-1168	the	abstract[58]	giv[58]	coref	25-10[150_58]
8-23	1169-1177	dominant	abstract[58]	giv[58]	_	_
8-24	1178-1186	families	abstract[58]	giv[58]	_	_
8-25	1187-1188	.	_	_	_	_

#Text=Still , the high diversity of produced congeners from each family and the little information known about factors and mechanisms linked to their production greatly complicates their study .
9-1	1189-1194	Still	_	_	_	_
9-2	1195-1196	,	_	_	_	_
9-3	1197-1200	the	abstract[59]	new[59]	_	_
9-4	1201-1205	high	abstract[59]	new[59]	_	_
9-5	1206-1215	diversity	abstract[59]	new[59]	_	_
9-6	1216-1218	of	abstract[59]	new[59]	_	_
9-7	1219-1227	produced	abstract[59]|substance[60]	new[59]|giv[60]	coref	14-8[87_60]
9-8	1228-1237	congeners	abstract[59]|substance[60]	new[59]|giv[60]	_	_
9-9	1238-1242	from	abstract[59]|substance[60]	new[59]|giv[60]	_	_
9-10	1243-1247	each	abstract[59]|substance[60]|person[61]	new[59]|giv[60]|new[61]	coref	17-13[107_61]
9-11	1248-1254	family	abstract[59]|substance[60]|person[61]	new[59]|giv[60]|new[61]	_	_
9-12	1255-1258	and	_	_	_	_
9-13	1259-1262	the	abstract[62]	new[62]	_	_
9-14	1263-1269	little	abstract[62]	new[62]	_	_
9-15	1270-1281	information	abstract[62]	new[62]	_	_
9-16	1282-1287	known	_	_	_	_
9-17	1288-1293	about	_	_	_	_
9-18	1294-1301	factors	abstract	new	_	_
9-19	1302-1305	and	_	_	_	_
9-20	1306-1316	mechanisms	abstract	new	ana	9-23
9-21	1317-1323	linked	_	_	_	_
9-22	1324-1326	to	_	_	_	_
9-23	1327-1332	their	abstract|abstract[66]	giv|giv[66]	ana	9-27
9-24	1333-1343	production	abstract[66]	giv[66]	_	_
9-25	1344-1351	greatly	_	_	_	_
9-26	1352-1363	complicates	_	_	_	_
9-27	1364-1369	their	abstract|abstract[68]	giv|new[68]	_	_
9-28	1370-1375	study	abstract[68]	new[68]	_	_
9-29	1376-1377	.	_	_	_	_

#Text=Potential cyanopeptides toxicity critically depends on the variants structure , but is still misunderstood and poorly documented .
10-1	1378-1387	Potential	abstract[70]	new[70]	coref	16-20[103_70]
10-2	1388-1401	cyanopeptides	substance|abstract[70]	giv|new[70]	coref	16-14[101_0]
10-3	1402-1410	toxicity	abstract[70]	new[70]	_	_
10-4	1411-1421	critically	_	_	_	_
10-5	1422-1429	depends	_	_	_	_
10-6	1430-1432	on	_	_	_	_
10-7	1433-1436	the	abstract[72]	new[72]	coref	18-4[113_72]
10-8	1437-1445	variants	object|abstract[72]	new|new[72]	coref	26-19[161_0]
10-9	1446-1455	structure	abstract[72]	new[72]	_	_
10-10	1456-1457	,	_	_	_	_
10-11	1458-1461	but	_	_	_	_
10-12	1462-1464	is	_	_	_	_
10-13	1465-1470	still	_	_	_	_
10-14	1471-1484	misunderstood	_	_	_	_
10-15	1485-1488	and	_	_	_	_
10-16	1489-1495	poorly	_	_	_	_
10-17	1496-1506	documented	_	_	_	_
10-18	1507-1508	.	_	_	_	_

#Text=MCs are hepatotoxic and readily accumulated in the liver from the specific binding to protein phosphatases 1 and 2A .
11-1	1509-1512	MCs	object	giv	coref	18-36[122_0]
11-2	1513-1516	are	_	_	_	_
11-3	1517-1528	hepatotoxic	_	_	_	_
11-4	1529-1532	and	_	_	_	_
11-5	1533-1540	readily	_	_	_	_
11-6	1541-1552	accumulated	_	_	_	_
11-7	1553-1555	in	_	_	_	_
11-8	1556-1559	the	object[74]	giv[74]	coref	12-18[0_74]
11-9	1560-1565	liver	object[74]	giv[74]	_	_
11-10	1566-1570	from	_	_	_	_
11-11	1571-1574	the	event[75]	new[75]	_	_
11-12	1575-1583	specific	event[75]	new[75]	_	_
11-13	1584-1591	binding	event[75]	new[75]	_	_
11-14	1592-1594	to	event[75]	new[75]	_	_
11-15	1595-1602	protein	event[75]|substance|abstract[77]	new[75]|new|new[77]	coref|coref	14-24|14-24[92_77]
11-16	1603-1615	phosphatases	event[75]|abstract[77]	new[75]|new[77]	_	_
11-17	1616-1617	1	event[75]|abstract[77]	new[75]|new[77]	_	_
11-18	1618-1621	and	event[75]|abstract[77]	new[75]|new[77]	_	_
11-19	1622-1624	2A	event[75]|abstract[77]	new[75]|new[77]	_	_
11-20	1625-1626	.	_	_	_	_

#Text=The latter causes disruption of cellular homeostasis , and , in most acute cases , leads to liver necrosis , as well as colorectal and liver cancer .
12-1	1627-1630	The	_	_	_	_
12-2	1631-1637	latter	_	_	_	_
12-3	1638-1644	causes	abstract	new	coref|none	18-17[117_0]|12-3[0_117]
12-4	1645-1655	disruption	abstract[78]	new[78]	_	_
12-5	1656-1658	of	abstract[78]	new[78]	_	_
12-6	1659-1667	cellular	abstract[78]|abstract[79]	new[78]|new[79]	_	_
12-7	1668-1679	homeostasis	abstract[78]|abstract[79]	new[78]|new[79]	_	_
12-8	1680-1681	,	_	_	_	_
12-9	1682-1685	and	_	_	_	_
12-10	1686-1687	,	_	_	_	_
12-11	1688-1690	in	_	_	_	_
12-12	1691-1695	most	abstract[80]	new[80]	_	_
12-13	1696-1701	acute	abstract[80]	new[80]	_	_
12-14	1702-1707	cases	abstract[80]	new[80]	_	_
12-15	1708-1709	,	_	_	_	_
12-16	1710-1715	leads	_	_	_	_
12-17	1716-1718	to	_	_	_	_
12-18	1719-1724	liver	object|object[82]	giv|new[82]	_	_
12-19	1725-1733	necrosis	object[82]	new[82]	_	_
12-20	1734-1735	,	_	_	_	_
12-21	1736-1738	as	_	_	_	_
12-22	1739-1743	well	_	_	_	_
12-23	1744-1746	as	_	_	_	_
12-24	1747-1757	colorectal	abstract[83]	new[83]	_	_
12-25	1758-1761	and	abstract[83]	new[83]	_	_
12-26	1762-1767	liver	abstract[83]	new[83]	_	_
12-27	1768-1774	cancer	abstract[83]	new[83]	_	_
12-28	1775-1776	.	_	_	_	_

#Text=Thus far , bioactive APs are considered non-toxic .
13-1	1777-1781	Thus	_	_	_	_
13-2	1782-1785	far	_	_	_	_
13-3	1786-1787	,	_	_	_	_
13-4	1788-1797	bioactive	object[84]	new[84]	_	_
13-5	1798-1801	APs	object[84]	new[84]	_	_
13-6	1802-1805	are	_	_	_	_
13-7	1806-1816	considered	_	_	_	_
13-8	1817-1826	non-toxic	_	_	_	_
13-9	1827-1828	.	_	_	_	_

#Text=Nevertheless , a few studies suggest that some APs congeners , such as AP-A , may demonstrate the potential to inhibit protease and protein phosphatases .
14-1	1829-1841	Nevertheless	_	_	_	_
14-2	1842-1843	,	_	_	_	_
14-3	1844-1845	a	abstract[85]	new[85]	_	_
14-4	1846-1849	few	abstract[85]	new[85]	_	_
14-5	1850-1857	studies	abstract[85]	new[85]	_	_
14-6	1858-1865	suggest	_	_	_	_
14-7	1866-1870	that	_	_	_	_
14-8	1871-1875	some	substance[87]	giv[87]	coref	18-24[119_87]
14-9	1876-1879	APs	abstract|substance[87]	giv|giv[87]	coref	18-39[123_0]
14-10	1880-1889	congeners	substance[87]	giv[87]	_	_
14-11	1890-1891	,	substance[87]	giv[87]	_	_
14-12	1892-1896	such	substance[87]	giv[87]	_	_
14-13	1897-1899	as	substance[87]	giv[87]	_	_
14-14	1900-1904	AP-A	substance[87]|substance	giv[87]|new	_	_
14-15	1905-1906	,	_	_	_	_
14-16	1907-1910	may	_	_	_	_
14-17	1911-1922	demonstrate	_	_	_	_
14-18	1923-1926	the	abstract[89]	new[89]	_	_
14-19	1927-1936	potential	abstract[89]	new[89]	_	_
14-20	1937-1939	to	_	_	_	_
14-21	1940-1947	inhibit	_	_	_	_
14-22	1948-1956	protease	substance	new	_	_
14-23	1957-1960	and	_	_	_	_
14-24	1961-1968	protein	substance|abstract[92]	giv|giv[92]	_	_
14-25	1969-1981	phosphatases	abstract[92]	giv[92]	_	_
14-26	1982-1983	.	_	_	_	_

#Text=Moreover , AP-B and -F induce cyanobacteria lysis , ultimately affecting the bioavailability of other cell-bound cyanotoxins .
15-1	1984-1992	Moreover	_	_	_	_
15-2	1993-1994	,	_	_	_	_
15-3	1995-1999	AP-B	substance	new	_	_
15-4	2000-2003	and	_	_	_	_
15-5	2004-2006	-F	abstract	new	_	_
15-6	2007-2013	induce	_	_	_	_
15-7	2014-2027	cyanobacteria	animal|abstract[96]	giv|new[96]	ana	26-7[0_96]
15-8	2028-2033	lysis	abstract[96]	new[96]	_	_
15-9	2034-2035	,	_	_	_	_
15-10	2036-2046	ultimately	_	_	_	_
15-11	2047-2056	affecting	_	_	_	_
15-12	2057-2060	the	abstract[97]	new[97]	_	_
15-13	2061-2076	bioavailability	abstract[97]	new[97]	_	_
15-14	2077-2079	of	abstract[97]	new[97]	_	_
15-15	2080-2085	other	abstract[97]|object[98]	new[97]|giv[98]	coref	30-6[198_98]
15-16	2086-2096	cell-bound	abstract[97]|object[98]	new[97]|giv[98]	_	_
15-17	2097-2108	cyanotoxins	abstract[97]|object[98]	new[97]|giv[98]	_	_
15-18	2109-2110	.	_	_	_	_

#Text=Accordingly , much still needs to be done on the unambiguous identification of these cyanopeptides and the assessment of their potential toxicity .
16-1	2111-2122	Accordingly	_	_	_	_
16-2	2123-2124	,	_	_	_	_
16-3	2125-2129	much	_	_	_	_
16-4	2130-2135	still	_	_	_	_
16-5	2136-2141	needs	_	_	_	_
16-6	2142-2144	to	_	_	_	_
16-7	2145-2147	be	_	_	_	_
16-8	2148-2152	done	_	_	_	_
16-9	2153-2155	on	_	_	_	_
16-10	2156-2159	the	abstract[99]|abstract[100]	new[99]|new[100]	_	_
16-11	2160-2171	unambiguous	abstract[99]|abstract[100]	new[99]|new[100]	_	_
16-12	2172-2186	identification	abstract[99]|abstract[100]	new[99]|new[100]	_	_
16-13	2187-2189	of	abstract[99]|abstract[100]	new[99]|new[100]	_	_
16-14	2190-2195	these	abstract[99]|abstract[100]|abstract[101]	new[99]|new[100]|giv[101]	coref	18-28[121_101]
16-15	2196-2209	cyanopeptides	abstract[99]|abstract[100]|abstract[101]	new[99]|new[100]|giv[101]	_	_
16-16	2210-2213	and	abstract[100]	new[100]	_	_
16-17	2214-2217	the	abstract[100]|abstract[102]	new[100]|new[102]	_	_
16-18	2218-2228	assessment	abstract[100]|abstract[102]	new[100]|new[102]	_	_
16-19	2229-2231	of	abstract[100]|abstract[102]	new[100]|new[102]	_	_
16-20	2232-2237	their	abstract[100]|abstract[102]|abstract[103]	new[100]|new[102]|giv[103]	_	_
16-21	2238-2247	potential	abstract[100]|abstract[102]|abstract[103]	new[100]|new[102]|giv[103]	_	_
16-22	2248-2256	toxicity	abstract[100]|abstract[102]|abstract[103]	new[100]|new[102]|giv[103]	_	_
16-23	2257-2258	.	_	_	_	_

#Text=Cyanopeptide ’s structures are characterized by cyclic or linear non-ribosomal peptides , each family possessing a characteristic substructure and some variable amino acids and peptides .
17-1	2259-2271	Cyanopeptide	abstract[104]|abstract[105]	new[104]|new[105]	_	_
17-2	2272-2274	’s	abstract[104]|abstract[105]	new[104]|new[105]	_	_
17-3	2275-2285	structures	abstract[105]	new[105]	_	_
17-4	2286-2289	are	_	_	_	_
17-5	2290-2303	characterized	_	_	_	_
17-6	2304-2306	by	_	_	_	_
17-7	2307-2313	cyclic	substance[106]	new[106]	coref	17-25[0_106]
17-8	2314-2316	or	substance[106]	new[106]	_	_
17-9	2317-2323	linear	substance[106]	new[106]	_	_
17-10	2324-2337	non-ribosomal	substance[106]	new[106]	_	_
17-11	2338-2346	peptides	substance[106]	new[106]	_	_
17-12	2347-2348	,	_	_	_	_
17-13	2349-2353	each	person[107]	giv[107]	_	_
17-14	2354-2360	family	person[107]	giv[107]	_	_
17-15	2361-2371	possessing	_	_	_	_
17-16	2372-2373	a	abstract[108]	new[108]	_	_
17-17	2374-2388	characteristic	abstract[108]	new[108]	_	_
17-18	2389-2401	substructure	abstract[108]	new[108]	_	_
17-19	2402-2405	and	_	_	_	_
17-20	2406-2410	some	abstract[110]	new[110]	coref	25-18[152_110]
17-21	2411-2419	variable	abstract[110]	new[110]	_	_
17-22	2420-2425	amino	object|abstract[110]	new|new[110]	_	_
17-23	2426-2431	acids	abstract[110]	new[110]	_	_
17-24	2432-2435	and	_	_	_	_
17-25	2436-2444	peptides	substance	giv	_	_
17-26	2445-2446	.	_	_	_	_

#Text=These variations in the core structure of each cyanopeptide multiply the number of combinations which is the cause of the large variety of potential congeners ; to date , more than 500 cyanopeptides , including 240 MCs and 96 APs have been identified .
18-1	2447-2452	These	abstract[112]	new[112]	_	_
18-2	2453-2463	variations	abstract[112]	new[112]	_	_
18-3	2464-2466	in	abstract[112]	new[112]	_	_
18-4	2467-2470	the	abstract[112]|abstract[113]	new[112]|giv[113]	coref	24-3[141_113]
18-5	2471-2475	core	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
18-6	2476-2485	structure	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
18-7	2486-2488	of	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
18-8	2489-2493	each	abstract[112]|abstract[113]|substance[114]	new[112]|giv[113]|new[114]	_	_
18-9	2494-2506	cyanopeptide	abstract[112]|abstract[113]|substance[114]	new[112]|giv[113]|new[114]	_	_
18-10	2507-2515	multiply	_	_	_	_
18-11	2516-2519	the	abstract[115]	new[115]	_	_
18-12	2520-2526	number	abstract[115]	new[115]	_	_
18-13	2527-2529	of	abstract[115]	new[115]	_	_
18-14	2530-2542	combinations	abstract[115]|abstract	new[115]|new	coref	25-3[149_0]
18-15	2543-2548	which	_	_	_	_
18-16	2549-2551	is	_	_	_	_
18-17	2552-2555	the	abstract[117]	new[117]	_	_
18-18	2556-2561	cause	abstract[117]	new[117]	_	_
18-19	2562-2564	of	abstract[117]	new[117]	_	_
18-20	2565-2568	the	abstract[117]|abstract[118]	new[117]|new[118]	_	_
18-21	2569-2574	large	abstract[117]|abstract[118]	new[117]|new[118]	_	_
18-22	2575-2582	variety	abstract[117]|abstract[118]	new[117]|new[118]	_	_
18-23	2583-2585	of	abstract[117]|abstract[118]	new[117]|new[118]	_	_
18-24	2586-2595	potential	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	coref	26-16[0_119]
18-25	2596-2605	congeners	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
18-26	2606-2607	;	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
18-27	2608-2610	to	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
18-28	2611-2615	date	abstract[117]|abstract[118]|substance[119]|time|abstract[121]	new[117]|new[118]|giv[119]|new|giv[121]	coref|coref	25-34[155_121]|25-37
18-29	2616-2617	,	abstract[117]|abstract[118]|substance[119]|abstract[121]	new[117]|new[118]|giv[119]|giv[121]	_	_
18-30	2618-2622	more	abstract[117]|abstract[118]|substance[119]|abstract[121]	new[117]|new[118]|giv[119]|giv[121]	_	_
18-31	2623-2627	than	abstract[117]|abstract[118]|substance[119]|abstract[121]	new[117]|new[118]|giv[119]|giv[121]	_	_
18-32	2628-2631	500	abstract[117]|abstract[118]|substance[119]|abstract[121]	new[117]|new[118]|giv[119]|giv[121]	_	_
18-33	2632-2645	cyanopeptides	abstract[117]|abstract[118]|substance[119]|abstract[121]	new[117]|new[118]|giv[119]|giv[121]	_	_
18-34	2646-2647	,	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
18-35	2648-2657	including	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
18-36	2658-2661	240	abstract[117]|abstract[118]|substance[119]|object[122]	new[117]|new[118]|giv[119]|giv[122]	coref	19-4[0_122]
18-37	2662-2665	MCs	abstract[117]|abstract[118]|substance[119]|object[122]	new[117]|new[118]|giv[119]|giv[122]	_	_
18-38	2666-2669	and	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
18-39	2670-2672	96	abstract[117]|abstract[118]|substance[119]|abstract[123]	new[117]|new[118]|giv[119]|giv[123]	coref	22-1[0_123]
18-40	2673-2676	APs	abstract[117]|abstract[118]|substance[119]|abstract[123]	new[117]|new[118]|giv[119]|giv[123]	_	_
18-41	2677-2681	have	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
18-42	2682-2686	been	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
18-43	2687-2697	identified	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
18-44	2698-2699	.	_	_	_	_

#Text=More specifically , MCs are cyclic heptapeptides (
19-1	2700-2704	More	_	_	_	_
19-2	2705-2717	specifically	_	_	_	_
19-3	2718-2719	,	_	_	_	_
19-4	2720-2723	MCs	substance	giv	coref	19-6[125_0]
19-5	2724-2727	are	_	_	_	_
19-6	2728-2734	cyclic	substance[125]	giv[125]	_	_
19-7	2735-2748	heptapeptides	substance[125]	giv[125]	_	_
19-8	2749-2750	(	_	_	_	_

#Text=Figure 1
20-1	2751-2757	Figure	object[126]	new[126]	coref	23-1[139_126]
20-2	2758-2759	1	object[126]	new[126]	_	_

#Text=) with a characteristic β-amino acid moiety named Adda ( 3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid ) , and two distinctive positions with the highest variation of monomers ( X and Z ) .
21-1	2760-2761	)	_	_	_	_
21-2	2762-2766	with	_	_	_	_
21-3	2767-2768	a	abstract[129]	new[129]	_	_
21-4	2769-2783	characteristic	abstract[129]	new[129]	_	_
21-5	2784-2791	β-amino	object|abstract[129]	new|new[129]	_	_
21-6	2792-2796	acid	substance|abstract[129]	new|new[129]	appos	21-11[131_0]
21-7	2797-2803	moiety	abstract[129]	new[129]	_	_
21-8	2804-2809	named	_	_	_	_
21-9	2810-2814	Adda	person	new	_	_
21-10	2815-2816	(	_	_	_	_
21-11	2817-2876	3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic	substance[131]	giv[131]	coref	24-19[0_131]
21-12	2877-2881	acid	substance[131]	giv[131]	_	_
21-13	2882-2883	)	_	_	_	_
21-14	2884-2885	,	_	_	_	_
21-15	2886-2889	and	_	_	_	_
21-16	2890-2893	two	abstract[132]	new[132]	_	_
21-17	2894-2905	distinctive	abstract[132]	new[132]	_	_
21-18	2906-2915	positions	abstract[132]	new[132]	_	_
21-19	2916-2920	with	abstract[132]	new[132]	_	_
21-20	2921-2924	the	abstract[132]|abstract[133]	new[132]|new[133]	_	_
21-21	2925-2932	highest	abstract[132]|abstract[133]	new[132]|new[133]	_	_
21-22	2933-2942	variation	abstract[132]|abstract[133]	new[132]|new[133]	_	_
21-23	2943-2945	of	abstract[132]|abstract[133]	new[132]|new[133]	_	_
21-24	2946-2954	monomers	abstract[132]|abstract[133]|abstract	new[132]|new[133]|new	_	_
21-25	2955-2956	(	_	_	_	_
21-26	2957-2958	X	person	new	_	_
21-27	2959-2962	and	_	_	_	_
21-28	2963-2964	Z	_	_	_	_
21-29	2965-2966	)	_	_	_	_
21-30	2967-2968	.	_	_	_	_

#Text=APs are cyclic peptides bound through a characteristic ureido-linkage (
22-1	2969-2972	APs	substance	giv	coref	22-3[137_0]
22-2	2973-2976	are	_	_	_	_
22-3	2977-2983	cyclic	substance[137]	giv[137]	ana	24-3[0_137]
22-4	2984-2992	peptides	substance[137]	giv[137]	_	_
22-5	2993-2998	bound	_	_	_	_
22-6	2999-3006	through	_	_	_	_
22-7	3007-3008	a	abstract[138]	new[138]	_	_
22-8	3009-3023	characteristic	abstract[138]	new[138]	_	_
22-9	3024-3038	ureido-linkage	abstract[138]	new[138]	_	_
22-10	3039-3040	(	_	_	_	_

#Text=Figure 1
23-1	3041-3047	Figure	object[139]	giv[139]	_	_
23-2	3048-3049	1	object[139]	giv[139]	_	_

#Text=) ; their structure is characterized as the following : AA1-CO-[Lys-AA3-AA4-MeAA5-AA6 ] with AA representing a variable amino acid residues and brackets , including the cyclic structure .
24-1	3050-3051	)	_	_	_	_
24-2	3052-3053	;	_	_	_	_
24-3	3054-3059	their	substance|abstract[141]	giv|giv[141]	coref	24-25[147_141]
24-4	3060-3069	structure	abstract[141]	giv[141]	_	_
24-5	3070-3072	is	_	_	_	_
24-6	3073-3086	characterized	_	_	_	_
24-7	3087-3089	as	_	_	_	_
24-8	3090-3093	the	_	_	_	_
24-9	3094-3103	following	_	_	_	_
24-10	3104-3105	:	_	_	_	_
24-11	3106-3135	AA1-CO-[Lys-AA3-AA4-MeAA5-AA6	abstract	new	_	_
24-12	3136-3137	]	_	_	_	_
24-13	3138-3142	with	_	_	_	_
24-14	3143-3145	AA	abstract	new	_	_
24-15	3146-3158	representing	_	_	_	_
24-16	3159-3160	a	abstract[145]	new[145]	_	_
24-17	3161-3169	variable	abstract[145]	new[145]	_	_
24-18	3170-3175	amino	abstract[145]	new[145]	_	_
24-19	3176-3180	acid	substance|abstract[145]	giv|new[145]	coref	25-6
24-20	3181-3189	residues	abstract[145]	new[145]	_	_
24-21	3190-3193	and	_	_	_	_
24-22	3194-3202	brackets	abstract[146]	new[146]	_	_
24-23	3203-3204	,	abstract[146]	new[146]	_	_
24-24	3205-3214	including	abstract[146]	new[146]	_	_
24-25	3215-3218	the	abstract[146]|abstract[147]	new[146]|giv[147]	_	_
24-26	3219-3225	cyclic	abstract[146]|abstract[147]	new[146]|giv[147]	_	_
24-27	3226-3235	structure	abstract[146]|abstract[147]	new[146]|giv[147]	_	_
24-28	3236-3237	.	_	_	_	_

#Text=Based on the various amino acid combinations identified for these two families , an extensive list of potential amino acids per variable sites can be proposed to enumerate all possible theoretical combinations of cyanopeptides identifiable to date .
25-1	3238-3243	Based	_	_	_	_
25-2	3244-3246	on	_	_	_	_
25-3	3247-3250	the	abstract[149]	giv[149]	coref	25-29[154_149]
25-4	3251-3258	various	abstract[149]	giv[149]	_	_
25-5	3259-3264	amino	abstract[149]	giv[149]	_	_
25-6	3265-3269	acid	substance|abstract[149]	giv|giv[149]	_	_
25-7	3270-3282	combinations	abstract[149]	giv[149]	_	_
25-8	3283-3293	identified	_	_	_	_
25-9	3294-3297	for	_	_	_	_
25-10	3298-3303	these	abstract[150]	giv[150]	coref	12-3[0_150]
25-11	3304-3307	two	abstract[150]	giv[150]	_	_
25-12	3308-3316	families	abstract[150]	giv[150]	_	_
25-13	3317-3318	,	_	_	_	_
25-14	3319-3321	an	abstract[151]	new[151]	_	_
25-15	3322-3331	extensive	abstract[151]	new[151]	_	_
25-16	3332-3336	list	abstract[151]	new[151]	_	_
25-17	3337-3339	of	abstract[151]	new[151]	_	_
25-18	3340-3349	potential	abstract[151]|abstract[152]	new[151]|giv[152]	coref	26-36[163_152]
25-19	3350-3355	amino	abstract[151]|abstract[152]	new[151]|giv[152]	_	_
25-20	3356-3361	acids	abstract[151]|abstract[152]	new[151]|giv[152]	_	_
25-21	3362-3365	per	abstract[151]|abstract[152]	new[151]|giv[152]	_	_
25-22	3366-3374	variable	abstract[151]|abstract[152]|abstract[153]	new[151]|giv[152]|new[153]	_	_
25-23	3375-3380	sites	abstract[151]|abstract[152]|abstract[153]	new[151]|giv[152]|new[153]	_	_
25-24	3381-3384	can	_	_	_	_
25-25	3385-3387	be	_	_	_	_
25-26	3388-3396	proposed	_	_	_	_
25-27	3397-3399	to	_	_	_	_
25-28	3400-3409	enumerate	_	_	_	_
25-29	3410-3413	all	abstract[154]	giv[154]	coref	26-3[157_154]
25-30	3414-3422	possible	abstract[154]	giv[154]	_	_
25-31	3423-3434	theoretical	abstract[154]	giv[154]	_	_
25-32	3435-3447	combinations	abstract[154]	giv[154]	_	_
25-33	3448-3450	of	abstract[154]	giv[154]	_	_
25-34	3451-3464	cyanopeptides	abstract[154]|object[155]	giv[154]|giv[155]	coref	36-16[251_155]
25-35	3465-3477	identifiable	abstract[154]|object[155]	giv[154]|giv[155]	_	_
25-36	3478-3480	to	_	_	_	_
25-37	3481-3485	date	time	giv	_	_
25-38	3486-3487	.	_	_	_	_

#Text=Based on the proposed combinations , one could theoretically propose a significantly higher number of congeners , although most of the variants may not occur naturally in practice , due to the low frequency of some amino acids in the possible combinations .
26-1	3488-3493	Based	_	_	_	_
26-2	3494-3496	on	_	_	_	_
26-3	3497-3500	the	abstract[157]	giv[157]	coref	26-40[164_157]
26-4	3501-3509	proposed	abstract[157]	giv[157]	_	_
26-5	3510-3522	combinations	abstract[157]	giv[157]	_	_
26-6	3523-3524	,	_	_	_	_
26-7	3525-3528	one	abstract	giv	_	_
26-8	3529-3534	could	_	_	_	_
26-9	3535-3548	theoretically	_	_	_	_
26-10	3549-3556	propose	_	_	_	_
26-11	3557-3558	a	quantity[159]	new[159]	_	_
26-12	3559-3572	significantly	quantity[159]	new[159]	_	_
26-13	3573-3579	higher	quantity[159]	new[159]	_	_
26-14	3580-3586	number	quantity[159]	new[159]	_	_
26-15	3587-3589	of	quantity[159]	new[159]	_	_
26-16	3590-3599	congeners	quantity[159]|substance	new[159]|giv	coref	36-29[254_0]
26-17	3600-3601	,	_	_	_	_
26-18	3602-3610	although	_	_	_	_
26-19	3611-3615	most	object[161]	giv[161]	_	_
26-20	3616-3618	of	object[161]	giv[161]	_	_
26-21	3619-3622	the	object[161]	giv[161]	_	_
26-22	3623-3631	variants	object[161]	giv[161]	_	_
26-23	3632-3635	may	_	_	_	_
26-24	3636-3639	not	_	_	_	_
26-25	3640-3645	occur	_	_	_	_
26-26	3646-3655	naturally	_	_	_	_
26-27	3656-3658	in	_	_	_	_
26-28	3659-3667	practice	_	_	_	_
26-29	3668-3669	,	_	_	_	_
26-30	3670-3673	due	_	_	_	_
26-31	3674-3676	to	_	_	_	_
26-32	3677-3680	the	abstract[162]	new[162]	_	_
26-33	3681-3684	low	abstract[162]	new[162]	_	_
26-34	3685-3694	frequency	abstract[162]	new[162]	_	_
26-35	3695-3697	of	abstract[162]	new[162]	_	_
26-36	3698-3702	some	abstract[162]|abstract[163]	new[162]|giv[163]	_	_
26-37	3703-3708	amino	abstract[162]|abstract[163]	new[162]|giv[163]	_	_
26-38	3709-3714	acids	abstract[162]|abstract[163]	new[162]|giv[163]	_	_
26-39	3715-3717	in	abstract[162]|abstract[163]	new[162]|giv[163]	_	_
26-40	3718-3721	the	abstract[162]|abstract[163]|abstract[164]	new[162]|giv[163]|giv[164]	_	_
26-41	3722-3730	possible	abstract[162]|abstract[163]|abstract[164]	new[162]|giv[163]|giv[164]	_	_
26-42	3731-3743	combinations	abstract[162]|abstract[163]|abstract[164]	new[162]|giv[163]|giv[164]	_	_
26-43	3744-3745	.	_	_	_	_

#Text=High-resolution mass spectrometry ( HRMS ) can use exact mass measurement coupled to database and software packages to become an increasingly more effective tool regarding the accurate identification of the suspect and unknown compounds without the use of certified standards , where target analysis is unfeasible .
27-1	3746-3761	High-resolution	abstract[166]	new[166]	appos	27-5[0_166]
27-2	3762-3766	mass	quantity|abstract[166]	new|new[166]	coref	27-10
27-3	3767-3779	spectrometry	abstract[166]	new[166]	_	_
27-4	3780-3781	(	_	_	_	_
27-5	3782-3786	HRMS	abstract	giv	coref	31-20
27-6	3787-3788	)	_	_	_	_
27-7	3789-3792	can	_	_	_	_
27-8	3793-3796	use	_	_	_	_
27-9	3797-3802	exact	abstract[169]	new[169]	_	_
27-10	3803-3807	mass	quantity|abstract[169]	giv|new[169]	coref	32-9[210_0]
27-11	3808-3819	measurement	abstract[169]	new[169]	_	_
27-12	3820-3827	coupled	_	_	_	_
27-13	3828-3830	to	_	_	_	_
27-14	3831-3839	database	abstract	new	_	_
27-15	3840-3843	and	_	_	_	_
27-16	3844-3852	software	abstract|abstract[172]	new|new[172]	_	_
27-17	3853-3861	packages	abstract[172]	new[172]	_	_
27-18	3862-3864	to	_	_	_	_
27-19	3865-3871	become	_	_	_	_
27-20	3872-3874	an	_	_	_	_
27-21	3875-3887	increasingly	_	_	_	_
27-22	3888-3892	more	_	_	_	_
27-23	3893-3902	effective	_	_	_	_
27-24	3903-3907	tool	_	_	_	_
27-25	3908-3917	regarding	_	_	_	_
27-26	3918-3921	the	abstract[173]	new[173]	coref	31-12[0_173]
27-27	3922-3930	accurate	abstract[173]	new[173]	_	_
27-28	3931-3945	identification	abstract[173]	new[173]	_	_
27-29	3946-3948	of	abstract[173]	new[173]	_	_
27-30	3949-3952	the	abstract[173]|substance[174]	new[173]|new[174]	_	_
27-31	3953-3960	suspect	abstract[173]|substance[174]	new[173]|new[174]	_	_
27-32	3961-3964	and	abstract[173]|substance[174]	new[173]|new[174]	_	_
27-33	3965-3972	unknown	abstract[173]|substance[174]	new[173]|new[174]	_	_
27-34	3973-3982	compounds	abstract[173]|substance[174]	new[173]|new[174]	_	_
27-35	3983-3990	without	abstract[173]|substance[174]	new[173]|new[174]	_	_
27-36	3991-3994	the	abstract[173]|substance[174]|abstract[175]	new[173]|new[174]|new[175]	_	_
27-37	3995-3998	use	abstract[173]|substance[174]|abstract[175]	new[173]|new[174]|new[175]	_	_
27-38	3999-4001	of	abstract[173]|substance[174]|abstract[175]	new[173]|new[174]|new[175]	_	_
27-39	4002-4011	certified	abstract[173]|substance[174]|abstract[175]|abstract[176]	new[173]|new[174]|new[175]|new[176]	_	_
27-40	4012-4021	standards	abstract[173]|substance[174]|abstract[175]|abstract[176]	new[173]|new[174]|new[175]|new[176]	_	_
27-41	4022-4023	,	_	_	_	_
27-42	4024-4029	where	_	_	_	_
27-43	4030-4036	target	abstract|abstract[178]	new|new[178]	coref	29-19[190_178]
27-44	4037-4045	analysis	abstract[178]	new[178]	_	_
27-45	4046-4048	is	_	_	_	_
27-46	4049-4059	unfeasible	_	_	_	_
27-47	4060-4061	.	_	_	_	_

#Text=Suspect and non-target screening are the two main strategies used for the exhaustive search of the known and unknown compound where almost no reference material is available .
28-1	4062-4069	Suspect	_	_	_	_
28-2	4070-4073	and	_	_	_	_
28-3	4074-4084	non-target	_	_	_	_
28-4	4085-4094	screening	abstract	new	coref	28-6[180_0]
28-5	4095-4098	are	_	_	_	_
28-6	4099-4102	the	abstract[180]	giv[180]	coref	29-9[0_180]
28-7	4103-4106	two	abstract[180]	giv[180]	_	_
28-8	4107-4111	main	abstract[180]	giv[180]	_	_
28-9	4112-4122	strategies	abstract[180]	giv[180]	_	_
28-10	4123-4127	used	_	_	_	_
28-11	4128-4131	for	_	_	_	_
28-12	4132-4135	the	event[181]	new[181]	_	_
28-13	4136-4146	exhaustive	event[181]	new[181]	_	_
28-14	4147-4153	search	event[181]	new[181]	_	_
28-15	4154-4156	of	event[181]	new[181]	_	_
28-16	4157-4160	the	event[181]|abstract[182]	new[181]|new[182]	coref	31-15[207_182]
28-17	4161-4166	known	event[181]|abstract[182]	new[181]|new[182]	_	_
28-18	4167-4170	and	event[181]|abstract[182]	new[181]|new[182]	_	_
28-19	4171-4178	unknown	event[181]|abstract[182]	new[181]|new[182]	_	_
28-20	4179-4187	compound	event[181]|abstract[182]	new[181]|new[182]	_	_
28-21	4188-4193	where	_	_	_	_
28-22	4194-4200	almost	_	_	_	_
28-23	4201-4203	no	abstract[184]	new[184]	_	_
28-24	4204-4213	reference	abstract|abstract[184]	new|new[184]	_	_
28-25	4214-4222	material	abstract[184]	new[184]	_	_
28-26	4223-4225	is	_	_	_	_
28-27	4226-4235	available	_	_	_	_
28-28	4236-4237	.	_	_	_	_

#Text=In recent years , the use of these screening techniques in the environmental field has greatly increased , particularly for the non-target analysis of pharmaceuticals , pesticides , hormones in surface and treated water .
29-1	4238-4240	In	_	_	_	_
29-2	4241-4247	recent	time[185]	new[185]	_	_
29-3	4248-4253	years	time[185]	new[185]	_	_
29-4	4254-4255	,	_	_	_	_
29-5	4256-4259	the	abstract[186]	new[186]	_	_
29-6	4260-4263	use	abstract[186]	new[186]	_	_
29-7	4264-4266	of	abstract[186]	new[186]	_	_
29-8	4267-4272	these	abstract[186]|abstract[188]	new[186]|new[188]	_	_
29-9	4273-4282	screening	abstract[186]|abstract|abstract[188]	new[186]|giv|new[188]	coref	33-3
29-10	4283-4293	techniques	abstract[186]|abstract[188]	new[186]|new[188]	_	_
29-11	4294-4296	in	abstract[186]|abstract[188]	new[186]|new[188]	_	_
29-12	4297-4300	the	abstract[186]|abstract[188]|abstract[189]	new[186]|new[188]|new[189]	_	_
29-13	4301-4314	environmental	abstract[186]|abstract[188]|abstract[189]	new[186]|new[188]|new[189]	_	_
29-14	4315-4320	field	abstract[186]|abstract[188]|abstract[189]	new[186]|new[188]|new[189]	_	_
29-15	4321-4324	has	_	_	_	_
29-16	4325-4332	greatly	_	_	_	_
29-17	4333-4342	increased	_	_	_	_
29-18	4343-4344	,	_	_	_	_
29-19	4345-4357	particularly	abstract[190]	giv[190]	coref	30-18[201_190]
29-20	4358-4361	for	abstract[190]	giv[190]	_	_
29-21	4362-4365	the	abstract[190]	giv[190]	_	_
29-22	4366-4376	non-target	abstract[190]	giv[190]	_	_
29-23	4377-4385	analysis	abstract[190]	giv[190]	_	_
29-24	4386-4388	of	abstract[190]	giv[190]	_	_
29-25	4389-4404	pharmaceuticals	abstract[190]|substance	giv[190]|new	_	_
29-26	4405-4406	,	abstract[190]	giv[190]	_	_
29-27	4407-4417	pesticides	abstract[190]|substance	giv[190]|new	_	_
29-28	4418-4419	,	abstract[190]	giv[190]	_	_
29-29	4420-4428	hormones	abstract[190]|substance[193]	giv[190]|new[193]	_	_
29-30	4429-4431	in	abstract[190]|substance[193]	giv[190]|new[193]	_	_
29-31	4432-4439	surface	abstract[190]|substance[193]|place	giv[190]|new[193]|new	_	_
29-32	4440-4443	and	abstract[190]	giv[190]	_	_
29-33	4444-4451	treated	abstract[190]|substance[195]	giv[190]|new[195]	coref	30-8[199_195]
29-34	4452-4457	water	abstract[190]|substance[195]	giv[190]|new[195]	_	_
29-35	4458-4459	.	_	_	_	_

#Text=Reversewise , the presence of cyanotoxins in surface water has only been investigated by few authors using this type of analysis .
30-1	4460-4471	Reversewise	abstract	new	_	_
30-2	4472-4473	,	_	_	_	_
30-3	4474-4477	the	abstract[197]	new[197]	_	_
30-4	4478-4486	presence	abstract[197]	new[197]	_	_
30-5	4487-4489	of	abstract[197]	new[197]	_	_
30-6	4490-4501	cyanotoxins	abstract[197]|object[198]	new[197]|giv[198]	coref	35-38[0_198]
30-7	4502-4504	in	abstract[197]|object[198]	new[197]|giv[198]	_	_
30-8	4505-4512	surface	abstract[197]|object[198]|substance[199]	new[197]|giv[198]|giv[199]	_	_
30-9	4513-4518	water	abstract[197]|object[198]|substance[199]	new[197]|giv[198]|giv[199]	_	_
30-10	4519-4522	has	_	_	_	_
30-11	4523-4527	only	_	_	_	_
30-12	4528-4532	been	_	_	_	_
30-13	4533-4545	investigated	_	_	_	_
30-14	4546-4548	by	_	_	_	_
30-15	4549-4552	few	person[200]	new[200]	_	_
30-16	4553-4560	authors	person[200]	new[200]	_	_
30-17	4561-4566	using	_	_	_	_
30-18	4567-4571	this	abstract[201]	giv[201]	coref	32-3[209_201]
30-19	4572-4576	type	abstract[201]	giv[201]	_	_
30-20	4577-4579	of	abstract[201]	giv[201]	_	_
30-21	4580-4588	analysis	abstract[201]	giv[201]	_	_
30-22	4589-4590	.	_	_	_	_

#Text=Isobaric interferences and co-eluting substances can represent major challenges in the identification process of a compound even when using HRMS .
31-1	4591-4599	Isobaric	abstract[202]	new[202]	_	_
31-2	4600-4613	interferences	abstract[202]	new[202]	_	_
31-3	4614-4617	and	_	_	_	_
31-4	4618-4628	co-eluting	substance[203]	new[203]	_	_
31-5	4629-4639	substances	substance[203]	new[203]	_	_
31-6	4640-4643	can	_	_	_	_
31-7	4644-4653	represent	_	_	_	_
31-8	4654-4659	major	abstract[204]	new[204]	_	_
31-9	4660-4670	challenges	abstract[204]	new[204]	_	_
31-10	4671-4673	in	abstract[204]	new[204]	_	_
31-11	4674-4677	the	abstract[204]|event[206]	new[204]|new[206]	_	_
31-12	4678-4692	identification	abstract[204]|abstract|event[206]	new[204]|giv|new[206]	coref	32-17[211_0]
31-13	4693-4700	process	abstract[204]|event[206]	new[204]|new[206]	_	_
31-14	4701-4703	of	abstract[204]|event[206]	new[204]|new[206]	_	_
31-15	4704-4705	a	abstract[204]|event[206]|abstract[207]	new[204]|new[206]|giv[207]	coref	32-32[215_207]
31-16	4706-4714	compound	abstract[204]|event[206]|abstract[207]	new[204]|new[206]|giv[207]	_	_
31-17	4715-4719	even	_	_	_	_
31-18	4720-4724	when	_	_	_	_
31-19	4725-4730	using	_	_	_	_
31-20	4731-4735	HRMS	abstract	giv	_	_
31-21	4736-4737	.	_	_	_	_

#Text=Moreover , a sole analysis , based on the accurate mass , is insufficient to confirm a structural identification , e. g. , determining the degradation by-products or metabolites related to a compound of interest .
32-1	4738-4746	Moreover	_	_	_	_
32-2	4747-4748	,	_	_	_	_
32-3	4749-4750	a	abstract[209]	giv[209]	_	_
32-4	4751-4755	sole	abstract[209]	giv[209]	_	_
32-5	4756-4764	analysis	abstract[209]	giv[209]	_	_
32-6	4765-4766	,	_	_	_	_
32-7	4767-4772	based	_	_	_	_
32-8	4773-4775	on	_	_	_	_
32-9	4776-4779	the	quantity[210]	giv[210]	coref	33-13[220_210]
32-10	4780-4788	accurate	quantity[210]	giv[210]	_	_
32-11	4789-4793	mass	quantity[210]	giv[210]	_	_
32-12	4794-4795	,	_	_	_	_
32-13	4796-4798	is	_	_	_	_
32-14	4799-4811	insufficient	_	_	_	_
32-15	4812-4814	to	_	_	_	_
32-16	4815-4822	confirm	_	_	_	_
32-17	4823-4824	a	abstract[211]	giv[211]	coref	33-38[0_211]
32-18	4825-4835	structural	abstract[211]	giv[211]	_	_
32-19	4836-4850	identification	abstract[211]	giv[211]	_	_
32-20	4851-4852	,	_	_	_	_
32-21	4853-4855	e.	_	_	_	_
32-22	4856-4858	g.	_	_	_	_
32-23	4859-4860	,	_	_	_	_
32-24	4861-4872	determining	_	_	_	_
32-25	4873-4876	the	substance[213]	new[213]	_	_
32-26	4877-4888	degradation	abstract|substance[213]	new|new[213]	_	_
32-27	4889-4900	by-products	substance[213]	new[213]	_	_
32-28	4901-4903	or	_	_	_	_
32-29	4904-4915	metabolites	substance	new	_	_
32-30	4916-4923	related	_	_	_	_
32-31	4924-4926	to	_	_	_	_
32-32	4927-4928	a	abstract[215]	giv[215]	_	_
32-33	4929-4937	compound	abstract[215]	giv[215]	_	_
32-34	4938-4940	of	abstract[215]	giv[215]	_	_
32-35	4941-4949	interest	abstract[215]	giv[215]	_	_
32-36	4950-4951	.	_	_	_	_

#Text=A non-target screening method should include various confirmatory elements , such as the accurate mass ( m/z ) , mass defect , isotopic pattern , charge states , adducts and fragmentation pattern that increase the confidence of identification .
33-1	4952-4953	A	abstract[217]	new[217]	_	_
33-2	4954-4964	non-target	abstract[217]	new[217]	_	_
33-3	4965-4974	screening	abstract|abstract[217]	giv|new[217]	coref	34-1[233_0]
33-4	4975-4981	method	abstract[217]	new[217]	_	_
33-5	4982-4988	should	_	_	_	_
33-6	4989-4996	include	_	_	_	_
33-7	4997-5004	various	abstract[219]	new[219]	_	_
33-8	5005-5017	confirmatory	place|abstract[219]	new|new[219]	_	_
33-9	5018-5026	elements	abstract[219]	new[219]	_	_
33-10	5027-5028	,	abstract[219]	new[219]	_	_
33-11	5029-5033	such	abstract[219]	new[219]	_	_
33-12	5034-5036	as	abstract[219]	new[219]	_	_
33-13	5037-5040	the	abstract[219]|quantity[220]	new[219]|giv[220]	appos	33-17[0_220]
33-14	5041-5049	accurate	abstract[219]|quantity[220]	new[219]|giv[220]	_	_
33-15	5050-5054	mass	abstract[219]|quantity[220]	new[219]|giv[220]	_	_
33-16	5055-5056	(	_	_	_	_
33-17	5057-5060	m/z	quantity	giv	coref	33-20
33-18	5061-5062	)	_	_	_	_
33-19	5063-5064	,	_	_	_	_
33-20	5065-5069	mass	quantity|abstract[223]	giv|new[223]	_	_
33-21	5070-5076	defect	abstract[223]	new[223]	_	_
33-22	5077-5078	,	_	_	_	_
33-23	5079-5087	isotopic	abstract|abstract[225]	new|new[225]	_	_
33-24	5088-5095	pattern	abstract[225]	new[225]	_	_
33-25	5096-5097	,	_	_	_	_
33-26	5098-5104	charge	abstract|abstract[227]	new|new[227]	_	_
33-27	5105-5111	states	abstract[227]	new[227]	_	_
33-28	5112-5113	,	_	_	_	_
33-29	5114-5121	adducts	abstract	new	_	_
33-30	5122-5125	and	_	_	_	_
33-31	5126-5139	fragmentation	abstract|abstract[230]	new|new[230]	_	_
33-32	5140-5147	pattern	abstract[230]	new[230]	_	_
33-33	5148-5152	that	_	_	_	_
33-34	5153-5161	increase	_	_	_	_
33-35	5162-5165	the	abstract[231]	new[231]	_	_
33-36	5166-5176	confidence	abstract[231]	new[231]	_	_
33-37	5177-5179	of	abstract[231]	new[231]	_	_
33-38	5180-5194	identification	abstract[231]|abstract	new[231]|giv	coref	35-13[239_0]
33-39	5195-5196	.	_	_	_	_

#Text=Suspect screening includes the benefit and disadvantage to depend on suspect lists .
34-1	5197-5204	Suspect	abstract[233]	giv[233]	_	_
34-2	5205-5214	screening	abstract[233]	giv[233]	_	_
34-3	5215-5223	includes	_	_	_	_
34-4	5224-5227	the	abstract[234]	new[234]	_	_
34-5	5228-5235	benefit	abstract[234]	new[234]	_	_
34-6	5236-5239	and	_	_	_	_
34-7	5240-5252	disadvantage	abstract	new	ana	35-1
34-8	5253-5255	to	_	_	_	_
34-9	5256-5262	depend	_	_	_	_
34-10	5263-5265	on	_	_	_	_
34-11	5266-5273	suspect	object[236]	new[236]	_	_
34-12	5274-5279	lists	object[236]	new[236]	_	_
34-13	5280-5281	.	_	_	_	_

#Text=It is mainly based on some of the information mentioned above for the identification , but a major drawback comes from a lack of data in online libraries for some small molecule families , i. e. , cyanotoxins , which allow a formal identification .
35-1	5282-5284	It	abstract	giv	_	_
35-2	5285-5287	is	_	_	_	_
35-3	5288-5294	mainly	_	_	_	_
35-4	5295-5300	based	_	_	_	_
35-5	5301-5303	on	_	_	_	_
35-6	5304-5308	some	_	_	_	_
35-7	5309-5311	of	_	_	_	_
35-8	5312-5315	the	abstract[238]	new[238]	_	_
35-9	5316-5327	information	abstract[238]	new[238]	_	_
35-10	5328-5337	mentioned	_	_	_	_
35-11	5338-5343	above	_	_	_	_
35-12	5344-5347	for	_	_	_	_
35-13	5348-5351	the	abstract[239]	giv[239]	coref	35-42[247_239]
35-14	5352-5366	identification	abstract[239]	giv[239]	_	_
35-15	5367-5368	,	_	_	_	_
35-16	5369-5372	but	_	_	_	_
35-17	5373-5374	a	abstract[240]	new[240]	_	_
35-18	5375-5380	major	abstract[240]	new[240]	_	_
35-19	5381-5389	drawback	abstract[240]	new[240]	_	_
35-20	5390-5395	comes	_	_	_	_
35-21	5396-5400	from	_	_	_	_
35-22	5401-5402	a	quantity[241]	new[241]	_	_
35-23	5403-5407	lack	quantity[241]	new[241]	_	_
35-24	5408-5410	of	quantity[241]	new[241]	_	_
35-25	5411-5415	data	quantity[241]|abstract	new[241]|new	_	_
35-26	5416-5418	in	quantity[241]	new[241]	_	_
35-27	5419-5425	online	quantity[241]|place[243]	new[241]|new[243]	_	_
35-28	5426-5435	libraries	quantity[241]|place[243]	new[241]|new[243]	_	_
35-29	5436-5439	for	quantity[241]|place[243]	new[241]|new[243]	_	_
35-30	5440-5444	some	quantity[241]|place[243]|abstract[245]	new[241]|new[243]|giv[245]	_	_
35-31	5445-5450	small	quantity[241]|place[243]|abstract[245]	new[241]|new[243]|giv[245]	_	_
35-32	5451-5459	molecule	quantity[241]|place[243]|abstract|abstract[245]	new[241]|new[243]|new|giv[245]	_	_
35-33	5460-5468	families	quantity[241]|place[243]|abstract[245]	new[241]|new[243]|giv[245]	_	_
35-34	5469-5470	,	_	_	_	_
35-35	5471-5473	i.	_	_	_	_
35-36	5474-5476	e.	_	_	_	_
35-37	5477-5478	,	_	_	_	_
35-38	5479-5490	cyanotoxins	object	giv	_	_
35-39	5491-5492	,	_	_	_	_
35-40	5493-5498	which	_	_	_	_
35-41	5499-5504	allow	_	_	_	_
35-42	5505-5506	a	abstract[247]	giv[247]	_	_
35-43	5507-5513	formal	abstract[247]	giv[247]	_	_
35-44	5514-5528	identification	abstract[247]	giv[247]	_	_
35-45	5529-5530	.	_	_	_	_

#Text=Nonetheless , considering the possibility to build specific in-house databases for the unambiguous identification of the known and unknown cyanopeptides is promising for the study and identification of less known congeners .
36-1	5531-5542	Nonetheless	_	_	_	_
36-2	5543-5544	,	_	_	_	_
36-3	5545-5556	considering	_	_	_	_
36-4	5557-5560	the	abstract[248]	new[248]	_	_
36-5	5561-5572	possibility	abstract[248]	new[248]	_	_
36-6	5573-5575	to	_	_	_	_
36-7	5576-5581	build	_	_	_	_
36-8	5582-5590	specific	abstract[249]	new[249]	_	_
36-9	5591-5599	in-house	abstract[249]	new[249]	_	_
36-10	5600-5609	databases	abstract[249]	new[249]	_	_
36-11	5610-5613	for	_	_	_	_
36-12	5614-5617	the	abstract[250]	new[250]	_	_
36-13	5618-5629	unambiguous	abstract[250]	new[250]	_	_
36-14	5630-5644	identification	abstract[250]	new[250]	_	_
36-15	5645-5647	of	abstract[250]	new[250]	_	_
36-16	5648-5651	the	abstract[250]|abstract[251]	new[250]|giv[251]	_	_
36-17	5652-5657	known	abstract[250]|abstract[251]	new[250]|giv[251]	_	_
36-18	5658-5661	and	abstract[250]|abstract[251]	new[250]|giv[251]	_	_
36-19	5662-5669	unknown	abstract[250]|abstract[251]	new[250]|giv[251]	_	_
36-20	5670-5683	cyanopeptides	abstract[250]|abstract[251]	new[250]|giv[251]	_	_
36-21	5684-5686	is	_	_	_	_
36-22	5687-5696	promising	_	_	_	_
36-23	5697-5700	for	_	_	_	_
36-24	5701-5704	the	abstract[252]	new[252]	_	_
36-25	5705-5710	study	abstract[252]	new[252]	_	_
36-26	5711-5714	and	_	_	_	_
36-27	5715-5729	identification	abstract[253]	new[253]	_	_
36-28	5730-5732	of	abstract[253]	new[253]	_	_
36-29	5733-5737	less	abstract[253]|substance[254]	new[253]|giv[254]	_	_
36-30	5738-5743	known	abstract[253]|substance[254]	new[253]|giv[254]	_	_
36-31	5744-5753	congeners	abstract[253]|substance[254]	new[253]|giv[254]	_	_
36-32	5754-5755	.	_	_	_	_
